Pediatric Heart Network Regents of the University of Michigan

摘要 这项提议利用密歇根大学的优势来支持密歇根先天性心脏病 中心是推动儿科心脏网络工作的富有成效的合作者、领导者和创新者 (PHN)致力于改善儿童和先天性心血管疾病的护理和预后。密西根 先天性心脏病中心的研究人员在许多先前和正在进行的PHN研究中发挥了关键作用，包括 领导单心室重建试验(儿科心脏外科首个多中心随机试验 外科)，指导几项PHN研究的生物库，并领导PHN综合心脏数据 和结果(IC卡)协作性。拥有强大临床和研究能力的中心的持续参与 基础设施，以及领导多中心协作研究的经验，以进一步推动重要的 PHN的工作。此外，当前时代还有新的挑战，包括进行更多的研究 高效、更好地利用不断增长的医疗保健数据，并研究新的疗法和 推动结果(特别是长期结果)进一步改善的工具，并根据需要量身定做 特定的临床和基因特征。我们的建议有两个目标-第一，我们的目标是作为一个协作性的 参与和领导PHN的工作，以解决儿科和妇科的重要问题 先天性心血管疾病。我们的成功记录，以及独特而全面的资源， 基础设施和专业知识将确保我们有能力全面参与PHN研究并领导高效和 合作研究。特别是，我们的专业知识特别涉及新疗法的研究和 设备、长期结果的评估(包括神经发育)和潜在的遗传因素， 这将使我们能够领导努力，解决这些领域的关键问题。我们拥有众多独立的教职员工 研究资金、培训资源和指导专业知识将培养我们成功竞争的能力 提供校外研究资金，以进一步支持公共卫生组织的活动。第二，我们的目标是引领创新数据 整合和分享努力，以促进新颖和高效的PHN研究。我们的调查人员有广泛的 这一领域的专业知识，包括跨现场大型数据集的开创性初始联系(由 NHLBI R01基金)，并创建一个最先进的平台，以在 儿科心脏重症监护联盟(PC4)。通过我们对最近成立的PHN IC卡的领导 协作，我们将努力将这一领域的创新带到PHN，包括整合现有和 新出现的数据使新的研究成为可能，并支持更有效的研究。 密歇根先天心脏中心的参与和领导将促进PHN的持续成功， 并使网络能够继续应对当前医疗保健和研究环境的挑战 目的：提高儿童和先天性心血管疾病的治疗水平和预后。

ABSTRACT This proposal leverages strengths across the University of Michigan to support the Michigan Congenital Heart Center as a productive collaborator, leader, and innovator in advancing efforts of the Pediatric Heart Network (PHN) toward improving care and outcomes of pediatric and congenital cardiovascular disease. Michigan Congenital Heart Center investigators have played key roles in many prior and ongoing PHN studies, including leading the Single Ventricle Reconstruction Trial (the first multicenter randomized trial in the pediatric cardiac surgery), directing the biorepository for several PHN studies, and leading the PHN Integrated CARdiac Data and Outcomes (iCARD) Collaborative. Continued participation of centers with strong clinical and research infrastructure, and experience in leading multi-center collaborative research is needed to further the important work of the PHN. In addition, there are new challenges in the current era, including conducting research more efficiently, better utilizing the ever-increasing volume of healthcare data, and investigating novel therapies and devices to drive further improvements in outcomes (particularly longer-term outcomes), and tailoring these to specific clinical and genetic profiles. Our proposal has two aims – first, we aim to serve as a collaborative participant and leader in furthering the work of the PHN to address important questions in pediatric and congenital cardiovascular disease. Our track record of success, and unique and comprehensive resources, infrastructure, and expertise will ensure our ability to participate fully across PHN studies and lead efficient and collaborative research. In particular, our expertise specifically related to the study of novel therapies and devices, assessment of longer-term outcomes (including neurodevelopment), and underlying genetic factors, will allow us to lead efforts to address key questions in these areas. Our numerous faculty with independent research funding, training resources, and mentoring expertise will foster our ability to compete successfully for extramural research funding to further support PHN activities. Second, we aim to lead innovative data integration and sharing efforts to foster novel and efficient PHN research. Our investigators have extensive expertise in this area, including pioneering initial linkages across large datasets in the field (supported by NHLBI R01 funding), and creating a state of the art platform to share information across centers within the Pediatric Cardiac Critical Care Consortium (PC4). Through our leadership of the recently formed PHN iCARD Collaborative, we will work to bring innovations in this area to the PHN, including integrating existing and emerging data to allow novel studies otherwise not possible, and to support more efficient conduct of research. Participation and leadership of the Michigan Congenital Heart Center will foster continued success of the PHN, and allow the network to meet the challenges of the current healthcare and research environments to continue to advance the treatment and outcomes of pediatric and congenital cardiovascular disease.